Diffuse Large B-Cell Lymphoma Version 1.2016.

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Diffuse large B-cell lymphoma (DLBCL) is recognized as a heterogeneous disease.
• Distinct molecular subtypes, including germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL), exhibit varied clinical behavior and treatment responses.
• A subset of DLBCL patients presents with concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas, DHL) or dual expression of MYC and BCL2 proteins (double-expressing DLBCL, DEL).

Purpose of the Study:

• To highlight the heterogeneity of DLBCL and its subtypes.
• To emphasize the need for accurate diagnostic methods.
• To address the current lack of established standards of care for specific DLBCL subtypes like PMBL, DHL, and DEL.

Main Methods:

• Review of current understanding of DLBCL heterogeneity.
• Discussion of diagnostic approaches including immunophenotyping and molecular testing.
• Reference to NCCN Guidelines for non-Hodgkin's lymphomas.

Main Results:

• DLBCL encompasses diverse molecular subtypes with differing prognoses.
• Specific subtypes like PMBL, DHL, and DEL require precise identification.
• Current treatment standards for these specific subtypes are not well-defined.

Conclusions:

• Accurate diagnosis of DLBCL subtypes is essential for appropriate patient management.
• Immunophenotyping and molecular testing play critical roles in subtyping.
• Further research and guideline development are needed for the management of PMBL, DHL, and DEL.